• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Brain Behav Immun . Immunometabolism perturbations in post-COVID-19 condition: interleukin-6 and monoamine oxidase interactions drive neuropsychiat

tetano

Editor, Senior Moderator
Brain Behav Immun


. 2025 Jul 4:S0889-1591(25)00261-2.
doi: 10.1016/j.bbi.2025.07.002. Online ahead of print. Immunometabolism perturbations in post-COVID-19 condition: interleukin-6 and monoamine oxidase interactions drive neuropsychiatric syndromes

Natacha S Ogando[SUP] 1 [/SUP], Mohamed Elaish[SUP] 2 [/SUP], Hajar Miranzadeh Mahabadi[SUP] 1 [/SUP], Kristopher D Langdon[SUP] 3 [/SUP], Sumit K Das[SUP] 4 [/SUP], Jeffrey T Joseph[SUP] 3 [/SUP], Esther Fujiwara[SUP] 5 [/SUP], Andrew Holt[SUP] 5 [/SUP], Karina Kaur[SUP] 1 [/SUP], William Branton[SUP] 1 [/SUP], Mahmoud Gheblawi[SUP] 6 [/SUP], Paige Lacy[SUP] 1 [/SUP], Gavin Y Oudit[SUP] 6 [/SUP], Tom C Hobman[SUP] 7 [/SUP], Grace Y Lam[SUP] 1 [/SUP], Christopher Power[SUP] 8 [/SUP]



Affiliations
Abstract

Neuropsychiatric disorders including depression or anxiety are common in persons with post-COVID-19 condition (PCC). In a clinical cohort, interleukin (IL)-1beta, -2, -6, -8, -10, and TNF-alpha were significantly elevated in serum from PCC compared to control subjects while serum IL-6 levels were selectively increased among PCC subjects with depression. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of primary human neural cells showed viral replication in astrocytes, although IL-6 was released by abortively-infected microglia. In C57BL6/J mice intranasally infected with mouse-adapted SARS-CoV-2, viral RNA was detected in the lungs and multiple brain regions, which persisted in 33 % of infected animals up to 21 days post-infection (dpi), associated with increased brainstem IL-6 expression. As catecholamines are implicated in mood and anxiety, we analyzed monoamine oxidase (MAO) expression, revealing elevated transcript and protein levels for both MAO isoforms in infected human and mouse brain tissues, particularly in glial cells, which was correlated with increased MAO enzymatic activity. Neurobehavioral assessments showed depressive behaviors until 7dpi, transitioning to anxiety behaviors by 21dpi among virus-infected mice, which was attenuated by MAO inhibition. These findings highlight the immunometabolic mechanisms, involving cytokine-enzyme interactions that contribute to PCC-associated neuropsychiatric syndromes while also identifying potential diagnostic and therapeutic options.

Keywords: Anxiety; COVID-19; Depression; IL-6; MAO; SARS-CoV-2.

 
Back
Top Bottom